<div class="white-sheet">
	<div class="content-slide">

		<!-- Secondary scene 1 -->
		<div class="content secondary-scene">

		<div class="title-bar red"></div>

		<div class="wrapper slide-3-3-4">

			<div class="vertical-nav">
                <ul class="two">
                    <li class="active"></li>
                    <li></li>
                </ul>
            </div>

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>

			</div>

			<div class="slide-title red two-line">
				Phase II study in refractory aplastic anaemia: <br />longer duration of transfusion independence
			</div>


			<div class="content-container">

				<table class="red">
					<tr>
						<th>Duration (days)</td>
						<th>Responders (n=17)</td>
						<th>Non-responders (n=26)</td>
						<th>Total (N=43)</td>
					</tr>
					<tr class="odd">
						<td style="font-weight:bold" colspan="4">Platelet transfusion independence</td>
					</tr>
					<tr>
						<td>Mean (SD)</td>
						<td>362.9 (402.92)</td>
						<td>29.8 (22.52)</td>
						<td>161.5 (298.84)</td>
					</tr>
					<tr class="odd">
						<td>Median (Range)</td>
						<td>200 (8–1096)</td>
						<td>27.5 (7–84)</td>
						<td>29 (7–1096)</td>
					</tr>
					<tr>
						<td colspan="4">RBC transfusion independence</td>
					</tr>
					<tr class="odd">
						<td>Mean (SD)</td>
						<td>339.9 (391.74)</td>
						<td>38 (26.48)</td>
						<td>157.3 (284.93)</td>
					</tr>
					<tr>
						<td>Median (Range)</td>
						<td>208 (15–1082)</td>
						<td>29 (8–115)</td>
						<td>34 (8–1082)</td>
					</tr>
				</table>

			</div>

		</div>


		<div class="references-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module3/GlaxoSmithKline-2014-DoF-ELT112523.pdf"><span>GlaxoSmithKline. Data on File. Clinical study report #ELT112523. 2014</span></li>
			</ul>

		</div>

		<div class="information-overlay overlay">

			<header>Phase II study in refractory aplastic anaemia: longer duration of transfusion independence</header>
				
			<ul>
				<li><span>The longest duration of platelet and RBC transfusion independence for each subject was used for this summary</span></li>
				<li><span>Platelet transfusion independence was defined as the duration of time with no platelet transfusion during treatment</span>
					<ul>
						<li><span>The longest platelet transfusion-free period for the entire treated population was 29 days (median); 200 days for responders and 27.5 day for non-responders </span></li>
					</ul>
				</li>
				<li><span>Red blood cell (RBC) transfusion independence was defined as the duration of the time with no RBC transfusions during treatment</span>
					<ul>
						<li><span>The longest RBC transfusion-free period for the entire study population was 34 days (median); 208 days for responders and 29 days for non-responders</span></li>
					</ul>
				</li>
			</ul>

		</div>

		</div>

		<!-- End of secondary scene 1 -->
		<!-- Secondary scene 2 -->
		<div class="content secondary-scene">

		<div class="title-bar blue"></div>

		<div class="wrapper slide-3-3-4a">

			<div class="vertical-nav">
                <ul class="two">
                    <li></li>
                    <li class="active"></li>
                </ul>
            </div>

			<div class="popups" style="position:absolute">
				<div data-effect="fade" data-duration="1000" data-target="references2-overlay" data-width="600" data-height="490" class="references-button show-overlay"></div>
				<div data-effect="fade" data-duration="1000" data-target="information2-overlay" data-width="600" data-height="490" class="information-button show-overlay"></div>
			</div>

			<div class="slide-title blue">
				Platelet and red blood cell transfusion independence
			</div>


			<div class="content-container">

				<table class="blue" style="text-align:center">
					<tr>
						<th rowspan="2"></th>
						<th rowspan="2">Patients,<br /> N </th>
						<th rowspan="2">Baseline<br /> transfusion<br /> independence</th>
						<th colspan="3">Post-baseline transfusion independence</th>
					</tr>
					<tr style="background: #4A2A94;font-size: 20px;color:white">
						<th>Dependent,<br /> n (%)</th>
						<th>Independent,*<br /> n (%)</th>
						<th>Total,<br />n (%)</th>
					</tr>
					<tr class="odd">
						<td colspan="6" style="text-align:left">Platelet transfusion independence</td>
					</tr>
					<tr>
						<td>All patients</td>
						<td>43</td>
						<td>Dependent<sup>†</sup><br />
							Independent<br />
							Total
						</td>
						<td>18 (42)<br />
							0<br />
							18 (42)
						</td>
						<td>
							21 (49)<br />
							4 (9)<br />
							25 (58)
						</td>
						<td>
							39 (91)<br />
							4 (9)<br />
							43 (100)
						</td>
					</tr>
					<tr class="odd">
						<td colspan="6" style="text-align:left">RBC transfusion independence</td>
					</tr>
					<tr>
						<td>All patients</td>
						<td>43</td>
						<td>
							Dependent<sup>†</sup><br />
							Independent<br />
							Total
						</td>
						<td>
							28 (65)<br />
							0<br />
							28 (65)
						</td>
						<td>
							9 (21)<br />
							6 (14)<br />
							15 (35)
						</td>
						<td>
							37 (86)<br />
							6 (14)<br />
							43 (100)
						</td>
					</tr>

				</table>

				<p class="small-print">*Independent for at least 4 weeks for platelets and at least 8 weeks for RBC; †At least one transfusion within 4 weeks of starting eltrombopag treatment for platelets and within 8 weeks for RBC</p>
			</div>

		</div>


		<div class="references2-overlay overlay">

			<header>References</header>
				
			<ul>
				<li class="navigateHref" data-navtarget="media/documents/module3/GlaxoSmithKline-2014-DoF-ELT112523.pdf"><span>GlaxoSmithKline. Data on File. Clinical study report #ELT112523. 2014</span></li>
			</ul>

		</div>


		<div class="information2-overlay overlay">

			<header>Platelet and red blood cell transfusion independence</header>
				
			<ul>
				<li><span>Of the 43 patients treated in the phase II study, 39 were platelet transfusion dependent at baseline</span>
					<ul>
						<li><span>Of these, 54% (21/39) became platelet transfusion independent</span>
							<ul>
								<li><span>Transfusion independence was defined as at least one period of 28 days without transfusion during the study</span></li>
							</ul>
						</li>
						<li><span>The four patients who were platelet transfusion independent at baseline maintained this during the study</span></li>
					</ul>
				</li>
				<li><span>Of the total number of patients in the study, 37 were RBC transfusion dependent at baseline</span>
					<ul>
						<li><span>Of these, 24% (9/37) achieved RBC transfusion independence</span>
							<ul>
								<li><span>In this case, transfusion independence was defined as at least one period of <br>56 days without transfusion during the study</span>
									<ul>
										<li><span>The six patients who were RBC transfusion independent at baseline remained independent during the study</span></li>
									</ul>
								</li>
							</ul>
						</li>
					</ul>
				</li>
			</ul>

		</div>

		</div>
		<!-- End of secondary scene 2 -->

	</div>
</div>